Suppliers / Qilu Antibiotics Linyi Pharmaceutical

Qilu Antibiotics Linyi Pharmaceutical

China Updated 9 July 2026

The public registers hold a second record for Qilu Antibiotics Linyi Pharmaceutical. The fuller profile, with 31 active US DMFs and 12 valid CEPs, is at Qilu Pharmaceutical. Figures on this page cover only this record.

Qilu Antibiotics Linyi Pharmaceutical is an API manufacturer based in China.

0
active US DMFs
0
valid CEPs
1
registered plants
0
filings across 0 regulators

Registered plants

Site FDA FEI
Dezhou City, China Not on file

What they file, and where

Molecule Regulators Docs
Exemestane SFDA (Saudi Arabia) 1
Meropenem SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Exemestane API Meropenem API

Questions about Qilu Antibiotics Linyi Pharmaceutical

Where does Qilu Antibiotics Linyi Pharmaceutical manufacture?
1 registered site is on record, in China (Dezhou City). Every site is listed on this page with the register it came from.
What does Qilu Antibiotics Linyi Pharmaceutical make?
2 molecules are on record against Qilu Antibiotics Linyi Pharmaceutical, including Exemestane and Meropenem. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Qilu Antibiotics Linyi Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Shandong Anhong Pharmaceutical shares 2 molecules Cipla shares 1 molecule Zydus Lifesciences shares 1 molecule Acs Dobfar shares 1 molecule Curia shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability